Recombinant Anti-GTPase HRAS antibody [Y132] - BSA and Azide free (ab239815)


  • Product name

    Anti-GTPase HRAS antibody [Y132] - BSA and Azide free
    See all GTPase HRAS primary antibodies
  • Description

    Rabbit monoclonal [Y132] to GTPase HRAS - BSA and Azide free
  • Host species

  • Tested applications

    Suitable for: IP, WBmore details
    Unsuitable for: IHC
  • Species reactivity

    Reacts with: Mouse, Rat, Human
    Predicted to work with: Chicken
  • Immunogen

    Synthetic peptide within Human GTPase HRAS aa 150 to the C-terminus (C terminal). The exact sequence is proprietary.

  • General notes

    Ab239815 is the carrier-free version of ab32417. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.


    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab239815 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab239815 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Detects a band of approximately 21 kDa (predicted molecular weight: 21 kDa).
  • Application notes
    Is unsuitable for IHC.
  • Target

    • Function

      Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
    • Involvement in disease

      Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
      Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
      Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
      Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
      Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
      Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
    • Sequence similarities

      Belongs to the small GTPase superfamily. Ras family.
    • Post-translational

      Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
      S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
    • Cellular localization

      Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
    • Information by UniProt
    • Database links

    • Alternative names

      • C BAS/HAS antibody
      • c H ras antibody
      • C HA RAS1 antibody
      • c has/bas p21 protein antibody
      • c ras Ki 2 activated oncogene antibody
      • c-H-ras antibody
      • CTLO antibody
      • GTP and GDP binding peptide B antibody
      • GTPase HRas, N-terminally processed antibody
      • H Ras 1 antibody
      • H RASIDX antibody
      • H-Ras-1 antibody
      • Ha Ras antibody
      • Ha Ras1 proto oncoprotein antibody
      • Ha-Ras antibody
      • HAMSV antibody
      • Harvey rat sarcoma viral oncogene homolog antibody
      • Harvey rat sarcoma viral oncoprotein antibody
      • HRAS antibody
      • HRAS1 antibody
      • K ras antibody
      • N ras antibody
      • p19 H RasIDX protein antibody
      • p21ras antibody
      • Ras family small GTP binding protein H Ras antibody
      • RASH_HUMAN antibody
      • RASH1 antibody
      • Transformation gene oncogene HAMSV antibody
      • Transforming protein p21 antibody
      • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
      • VH Ras antibody
      • vHa RAS antibody
      see all


    • ab32417 (purified) at 1/60 immunoprecipitating GTPase in 10 µg mouse brain whole cell lysate (Lanes 1 and 2, observed at 21 kDa). Lane 3 - PBS. For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10,000 dilution. Blocking buffer and concentration: 5% NFDM/TBST Dilution buffer and concentration: 5% NFDM/TBST

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32417).


    ab239815 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab239815.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact

    Sign up